piracetam has been researched along with Aging in 56 studies
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.
Aging: The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To study the effect of acteoside on the expression of neurotrophin-3 (NT-3) in brain tissues of subacute aging mice induced by D-galactose (D-Gal) combined with aluminum trichloride (AlCl3)." | 7.80 | [Acteoside enhances expression of neurotrophin-3 in brain tissues of subacute aging mice induced by D-galactose combined with aluminum trichloride]. ( Gao, L; He, Y; Huo, S; Peng, X; Yan, M, 2014) |
| " This study was designed to compare the effects of levetiracetam, an antiepileptic drug, on memory deficits associated with normal aging and AD in mouse models." | 7.79 | Effects of levetiracetam, an antiepileptic drug, on memory impairments associated with aging and Alzheimer's disease in mice. ( Devi, L; Ohno, M, 2013) |
| "The authors examined sodium concentrations from 97 oxcarbazepine-treated (OXC) and 451 carbamazepine-treated (CBZ) patients with epilepsy using cross-section and follow-up studies." | 7.73 | Hyponatremia from oxcarbazepine and carbamazepine. ( Dong, X; Leppik, IE; Rarick, J; White, J, 2005) |
| "Extensive research of the recent years has demonstrated that piracetam is effective in the treatment of cognitive decline in aging and dementia." | 4.80 | Piracetam: novelty in a unique mode of action. ( Eckert, A; Eckert, GP; Müller, WE, 1999) |
| "Many of the neurochemical changes associated with aging brain, particularly lower choline acetyltransferase and higher monoamine oxidase, occur with greater severity in senile dementia, Alzheimer's type (SDAT)." | 4.76 | Chemotherapy of cognitive disorders in geriatric subjects. ( Gershon, S; Goodnick, P, 1984) |
| "To study the effect of acteoside on the expression of neurotrophin-3 (NT-3) in brain tissues of subacute aging mice induced by D-galactose (D-Gal) combined with aluminum trichloride (AlCl3)." | 3.80 | [Acteoside enhances expression of neurotrophin-3 in brain tissues of subacute aging mice induced by D-galactose combined with aluminum trichloride]. ( Gao, L; He, Y; Huo, S; Peng, X; Yan, M, 2014) |
| " This study was designed to compare the effects of levetiracetam, an antiepileptic drug, on memory deficits associated with normal aging and AD in mouse models." | 3.79 | Effects of levetiracetam, an antiepileptic drug, on memory impairments associated with aging and Alzheimer's disease in mice. ( Devi, L; Ohno, M, 2013) |
| " The increased risk associated with piracetam may reflect awareness of memory problems before any diagnosis of dementia has been made." | 3.75 | Sociodemographic and lifestyle risk factors for incident dementia and cognitive decline in the HYVET. ( Beckett, N; Bulpitt, C; de Vernejoul, MC; Fletcher, A; Gainsborough, N; Geneva, M; Lu, FH; Peters, R; Poulter, R; Tzekova, M; Williams, B, 2009) |
| "The authors examined sodium concentrations from 97 oxcarbazepine-treated (OXC) and 451 carbamazepine-treated (CBZ) patients with epilepsy using cross-section and follow-up studies." | 3.73 | Hyponatremia from oxcarbazepine and carbamazepine. ( Dong, X; Leppik, IE; Rarick, J; White, J, 2005) |
| " Elevated plus-maze and passive-avoidance apparatus served as the exteroceptive behavioral models, and diazepam-, scopolamine-, and aging-induced amnesia served as the interoceptive behavioral models." | 3.72 | Ascorbic Acid: a promising memory-enhancer in mice. ( Dhingra, D; Parle, M, 2003) |
| "The purpose of this analysis was to compare treatment-emergent adverse events (TEAE) related to use of levetiracetam (LEV) reported by young and elderly patients with anxiety and cognitive disorders, and young epilepsy patients." | 3.72 | Tolerability of levetiracetam in elderly patients with CNS disorders. ( Cramer, JA; Edrich, P; Krämer, G; Leppik, IE; Rue, KD, 2003) |
| "In order to test the hypothesis that piracetam improves cognitive functions by restoring biochemical deficits of the aging brain, we investigated the effects of piracetam treatment (300 mg/kg daily for 6 weeks) on the active avoidance performance of young and aged rats." | 3.70 | Piracetam improves cognitive performance by restoring neurochemical deficits of the aged rat brain. ( Bartsch, R; Müller, WE; Rostock, A; Scheuer, K, 1999) |
| "Levetiracetam is an effective antiepileptic drug in elderly individuals with cognitive impairment." | 2.75 | Levetiracetam: a practical option for seizure management in elderly patients with cognitive impairment. ( Hepler, M; Irwin, D; Jenssen, S; Lippa, CF; Pillai, J; Rosso, A, 2010) |
| "Epilepsy is one of the most common neurological conditions in the elderly, and the incidence of de novo geriatric epilepsy is rising." | 2.49 | [Epilepsy in the elderly]. ( Lossius, MI; Markhus, R; Nakken, KO; Sætre, E, 2013) |
| " Individualization of dosage and avoidance of unnecessary polypharmacy are essential for safe utilization of anti-epileptic drugs." | 2.44 | [Epilepsy in the elderly]. ( Yoshino, A, 2007) |
| "3." | 1.33 | Piracetam improves mitochondrial dysfunction following oxidative stress. ( Eckert, A; Hauptmann, S; Keil, U; Müller, WE; Scherping, I; Schuessel, K, 2006) |
| " Furthermore, the pharmacodynamic action of diuretics was not significantly altered in the elderly." | 1.30 | Renal handling of drugs in the healthy elderly. Creatinine clearance underestimates renal function and pharmacokinetics remain virtually unchanged. ( Bischoff, I; Block, S; Fliser, D; Hanses, A; Joest, M; Mutschler, E; Ritz, E, 1999) |
| "Piracetam was without effect on the performance of young animals but dose-dependently decreased the choice reaction times (two levers) in aged animals without affecting the other two parameters." | 1.29 | Effects of piracetam on indices of cognitive function in a delayed alternation task in young and aged rats. ( Hubert, I; Lenègre, A; Milinkevitch, D; Porsolt, RD; Roux, S, 1994) |
| "Memory deficits were induced by the muscarinic cholinoceptor antagonist scopolamine (in young and old rats and mice), by the alpha 2-adrenoceptor agonist clonidine, by electroconvulsive shock, and by hypoxy." | 1.29 | Effects of cytidine diphosphate choline on rats with memory deficits. ( Getova, D; Kehayov, RA; Lazarova, MB; Mosharrof, AH; Petkov, VD; Petkov, VV; Vaglenova, J, 1993) |
| "Rats treated with piracetam (500 mg/kg, p." | 1.28 | Effect of piracetam administration on 3H-N-methylscopolamine binding in cerebral cortex of young and old rats. ( Marinho, MM; Sousa, FC; Viana, GS, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 19 (33.93) | 18.7374 |
| 1990's | 19 (33.93) | 18.2507 |
| 2000's | 7 (12.50) | 29.6817 |
| 2010's | 11 (19.64) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, P | 1 |
| Sun, H | 1 |
| Liu, D | 1 |
| Jiao, Z | 1 |
| Yue, S | 1 |
| He, X | 1 |
| Xia, W | 1 |
| Ji, J | 1 |
| Xiang, L | 1 |
| Devi, L | 1 |
| Ohno, M | 1 |
| Nakken, KO | 1 |
| Sætre, E | 1 |
| Markhus, R | 1 |
| Lossius, MI | 1 |
| Spiegel, AM | 1 |
| Koh, MT | 2 |
| Vogt, NM | 1 |
| Rapp, PR | 1 |
| Gallagher, M | 2 |
| Gao, L | 1 |
| Peng, X | 1 |
| Huo, S | 1 |
| He, Y | 1 |
| Yan, M | 1 |
| Robitsek, J | 1 |
| Ratner, MH | 1 |
| Stewart, T | 1 |
| Eichenbaum, H | 1 |
| Farb, DH | 1 |
| Stockburger, C | 1 |
| Miano, D | 1 |
| Baeumlisberger, M | 1 |
| Pallas, T | 1 |
| Arrey, TN | 1 |
| Karas, M | 1 |
| Friedland, K | 1 |
| Müller, WE | 8 |
| Lippa, CF | 1 |
| Rosso, A | 1 |
| Hepler, M | 1 |
| Jenssen, S | 1 |
| Pillai, J | 1 |
| Irwin, D | 1 |
| Peters, R | 1 |
| Beckett, N | 1 |
| Geneva, M | 1 |
| Tzekova, M | 1 |
| Lu, FH | 1 |
| Poulter, R | 1 |
| Gainsborough, N | 1 |
| Williams, B | 1 |
| de Vernejoul, MC | 1 |
| Fletcher, A | 1 |
| Bulpitt, C | 1 |
| Haberman, RP | 1 |
| Foti, S | 1 |
| McCown, TJ | 1 |
| Sharma, K | 1 |
| Bhatnagar, M | 1 |
| Kulkarni, SK | 1 |
| Boido, D | 1 |
| Farisello, P | 1 |
| Cesca, F | 1 |
| Ferrea, E | 1 |
| Valtorta, F | 1 |
| Benfenati, F | 1 |
| Baldelli, P | 1 |
| Parle, M | 1 |
| Dhingra, D | 1 |
| Cramer, JA | 1 |
| Leppik, IE | 2 |
| Rue, KD | 1 |
| Edrich, P | 1 |
| Krämer, G | 1 |
| Dedeurwaerdere, S | 1 |
| Boon, P | 1 |
| De Smedt, T | 1 |
| Claeys, P | 1 |
| Raedt, R | 1 |
| Bosman, T | 1 |
| Van Hese, P | 1 |
| Van Maele, G | 1 |
| Vonck, K | 1 |
| Keil, U | 1 |
| Scherping, I | 1 |
| Hauptmann, S | 1 |
| Schuessel, K | 1 |
| Eckert, A | 2 |
| Dong, X | 1 |
| White, J | 1 |
| Rarick, J | 1 |
| Yoshino, A | 1 |
| Wittenborn, JR | 1 |
| Goodnick, P | 1 |
| Gershon, S | 1 |
| Jänicke, B | 2 |
| Wrobel, D | 1 |
| Jamieson, DD | 1 |
| Taylor, KM | 1 |
| Platt, D | 2 |
| Oswald, WD | 1 |
| Matejcek, M | 1 |
| Lukaschek, K | 1 |
| Dennler, HJ | 1 |
| Oswald, B | 1 |
| Bartus, RT | 1 |
| Dean, RL | 1 |
| Sherman, KA | 1 |
| Friedman, E | 1 |
| Beer, B | 1 |
| Roux, S | 1 |
| Hubert, I | 1 |
| Lenègre, A | 1 |
| Milinkevitch, D | 1 |
| Porsolt, RD | 1 |
| Petkov, VD | 3 |
| Kehayov, RA | 1 |
| Mosharrof, AH | 1 |
| Petkov, VV | 3 |
| Getova, D | 1 |
| Lazarova, MB | 1 |
| Vaglenova, J | 1 |
| Cohen, SA | 1 |
| Salimov, R | 1 |
| Salimova, N | 1 |
| Shvets, L | 1 |
| Shvets, N | 1 |
| Nagy, IZ | 1 |
| Koch, S | 1 |
| Scheuer, K | 2 |
| Rostock, A | 2 |
| Bartsch, R | 2 |
| Israël, L | 1 |
| Myslinski, M | 1 |
| Dubos, G | 1 |
| Mélac, M | 1 |
| Ryzhavskiĭ, BIa | 1 |
| Cheprakova, VA | 1 |
| Tsekatunov, DA | 1 |
| Dormehl, IC | 1 |
| Jordaan, B | 1 |
| Oliver, DW | 1 |
| Croft, S | 1 |
| Eckert, GP | 1 |
| Fliser, D | 1 |
| Bischoff, I | 1 |
| Hanses, A | 1 |
| Block, S | 1 |
| Joest, M | 1 |
| Ritz, E | 1 |
| Mutschler, E | 1 |
| Clemens, JA | 1 |
| Fuller, RW | 1 |
| Dorn, M | 1 |
| Viana, GS | 1 |
| Marinho, MM | 1 |
| Sousa, FC | 1 |
| Mondadori, C | 2 |
| Buerki, H | 2 |
| Borkowski, J | 2 |
| Radeke, E | 1 |
| Ducret, T | 2 |
| Glatt, A | 1 |
| Stancheva, SL | 1 |
| Hadjiivanova, CI | 1 |
| Coper, H | 1 |
| Heiss, WD | 1 |
| Szelies, B | 1 |
| Kessler, J | 1 |
| Herholz, K | 1 |
| Belcheva, S | 1 |
| Stoyanova, V | 1 |
| Wustmann, C | 1 |
| Blaschke, M | 1 |
| Rudolph, E | 1 |
| Fischer, HD | 1 |
| Schmidt, J | 1 |
| Yamamoto, M | 1 |
| Iwai, A | 1 |
| Kawabata, S | 1 |
| Ozawa, Y | 1 |
| Shimizu, M | 1 |
| Pilch, H | 2 |
| Classen, W | 1 |
| Schadé, A | 1 |
| Giurgea, G | 1 |
| Pavlovskaia, NI | 1 |
| Vorob'eva, TV | 1 |
| Zelenin, VA | 1 |
| Amin, MM | 1 |
| Khan, P | 1 |
| Lehmann, HE | 1 |
| Mirmiran, J | 1 |
| Mühlberg, W | 1 |
| Rieck, W | 1 |
| Poschel, BP | 1 |
| Ho, PM | 1 |
| Ninteman, FW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Network-Level Mechanisms for Preclinical Alzheimer's Disease Development[NCT03461861] | Phase 2 | 26 participants (Actual) | Interventional | 2019-04-11 | Completed | ||
| Bridging Cognitive Aging in Rodents to Man Using fMRI in Amnestic MCI[NCT01044758] | Phase 2 | 96 participants (Actual) | Interventional | 2009-12-31 | Completed | ||
| Brain Changes in Pediatric Obstructive Sleep Apnea[NCT05368077] | 70 participants (Anticipated) | Interventional | 2022-05-14 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The seed-based functional connectivity strengths of the hippocampus network and the default mode network will be employed to measure the changes between AGB101 and Placebo perturbation. The functional connectivity strengths will be measured with the median of the Pearson cross-correlation coefficients over entire brain regions. (NCT03461861)
Timeframe: 2 weeks after treatment between AGB101 and Placebo
| Intervention | Pearson coefficient (Median) |
|---|---|
| AGB101 220 mg | 0.233 |
| Placebo | 0.318 |
Rey Auditory Verbal Learning Test (AVLT), delayed recall Scaled integer will be employed to measure the episodic memory changes before and after AGB101 treatment. The AVLT score will be recorded as a standard score. The theoretical range: min 50, max 155, the higher the better. The higher the number is, the better the memory. It is an integer number. (NCT03461861)
Timeframe: Placebo vs AGB101 2 weeks after treatment paired t-test
| Intervention | score on a scale (Mean) |
|---|---|
| AGB101 220 mg | 108 |
| Placebo | 105 |
Mnemonic similarity task which assesses long term memory function. Scale ranges from 0-100 with higher scores indicating better memory performance. (NCT01044758)
Timeframe: 2 weeks
| Intervention | percent correct recalled (Mean) |
|---|---|
| aMCI_62.5 | 38 |
| aMCI_62.5 Placebo | 33 |
| aMCI_125 | 33 |
| aMCI_125 Placebo | 28 |
| aMCI_250 | 34 |
| aMCI_250 Placebo | 31 |
| Age Matched Control | 44 |
Measurement of average brain activity in the dentate gyrus / CA3 subregion of the hippocampus measured with BOLD functional MRI in patients with mild cognitive impairment on placebo and on drug compared to average brain activity in this brain area in control subjects. (NCT01044758)
Timeframe: 2 weeks
| Intervention | mean beta coefficient (Mean) |
|---|---|
| aMCI_62.5 | -0.1203 |
| aMCI_62.5 Placebo | 0.4353 |
| aMCI_125 | -0.2238 |
| aMCI_125 Placebo | 0.8814 |
| aMCI_250 | 0.3928 |
| aMCI_250 Placebo | 0.4825 |
| Age Matched Control | -.02507 |
7 reviews available for piracetam and Aging
| Article | Year |
|---|---|
[Epilepsy in the elderly].
Topics: Age Factors; Aged; Aging; Anticonvulsants; Dose-Response Relationship, Drug; Epilepsy; Humans; Isoxa | 2013 |
[Epilepsy in the elderly].
Topics: Aged; Aged, 80 and over; Aging; Amines; Anticonvulsants; Cerebrovascular Disorders; Comorbidity; Cyc | 2007 |
Pharmacotherapy for age-related behavioral deficiencies.
Topics: Adult; Aged; Aging; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Brain; Central | 1981 |
Chemotherapy of cognitive disorders in geriatric subjects.
Topics: Adrenocorticotropic Hormone; Aged; Aging; Alzheimer Disease; Arecoline; Brain Chemistry; Choline; Co | 1984 |
On the possible role of nootropica in geriatric prevention and therapy.
Topics: Aging; Free Radical Scavengers; Humans; Nootropic Agents; Piracetam; Proline; Selegiline | 1996 |
Piracetam: novelty in a unique mode of action.
Topics: Aged; Aging; Animals; Blood Cells; Brain; Brain Diseases; Cell Membrane; Cerebrovascular Circulation | 1999 |
Chemical manipulation of some aspects of aging.
Topics: Aging; Animals; Ergolines; Estrus; Female; Humans; Longevity; Male; Monoamine Oxidase Inhibitors; Pi | 1978 |
6 trials available for piracetam and Aging
| Article | Year |
|---|---|
Levetiracetam: a practical option for seizure management in elderly patients with cognitive impairment.
Topics: Aged; Aged, 80 and over; Aging; Anticonvulsants; Cognition; Cognition Disorders; Disease-Free Surviv | 2010 |
[On the meaning of psychometrically operationalized therapeutic effects in the treatment of brain insufficiency phenomena caused by old age demonstrated by the "Nürnberger-Alters-Inventar" (author's transl)].
Topics: Activities of Daily Living; Aged; Aging; Cognition; Dihydroergotoxine; Electroencephalography; Human | 1982 |
[Combined therapies in family practice and hospitals. A controlled clinical study of a population of 162 patients with criteria of age-related memory disorders].
Topics: Aged; Aging; Ambulatory Care; Cognitive Behavioral Therapy; Combined Modality Therapy; Double-Blind | 1997 |
SPECT monitoring of improved cerebral blood flow during long-term treatment of elderly patients with nootropic drugs.
Topics: Administration, Oral; Aged; Aging; Brain; Cerebellum; Cerebrovascular Circulation; Cognition; Cross- | 1999 |
[Piracetam in premature biological aging. Double-blind study after preselection by drugs].
Topics: Aged; Aging; Double-Blind Method; Humans; Hypoxia, Brain; Piracetam; Placebos; Progeria; Pyrrolidino | 1978 |
Early organiform impairment test (OFIT). A new performance test for assessment of early cognitive impairment.
Topics: Adult; Aged; Aging; Clinical Trials as Topic; Cognition Disorders; Double-Blind Method; Female; Huma | 1985 |
43 other studies available for piracetam and Aging
| Article | Year |
|---|---|
Protective effect of a phenolic extract containing indoline amides from Portulaca oleracea against cognitive impairment in senescent mice induced by large dose of D-galactose /NaNO
Topics: Aging; Amides; Animals; Antioxidants; Cognitive Dysfunction; Disease Models, Animal; Galactose; Indo | 2017 |
Effects of levetiracetam, an antiepileptic drug, on memory impairments associated with aging and Alzheimer's disease in mice.
Topics: Aging; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Conditioning, Operant; Disease Mo | 2013 |
Hilar interneuron vulnerability distinguishes aged rats with memory impairment.
Topics: Aging; Animals; Antigens, Nuclear; Behavior, Animal; CA3 Region, Hippocampal; Cell Count; Cognition; | 2013 |
[Acteoside enhances expression of neurotrophin-3 in brain tissues of subacute aging mice induced by D-galactose combined with aluminum trichloride].
Topics: Aging; Aluminum Chloride; Aluminum Compounds; Animals; Antioxidants; Blotting, Western; Brain; Chlor | 2014 |
Combined administration of levetiracetam and valproic acid attenuates age-related hyperactivity of CA3 place cells, reduces place field area, and increases spatial information content in aged rat hippocampus.
Topics: Action Potentials; Aging; Animals; CA1 Region, Hippocampal; CA3 Region, Hippocampal; Central Nervous | 2015 |
A Mitochondrial Role of SV2a Protein in Aging and Alzheimer's Disease: Studies with Levetiracetam.
Topics: Adenosine Triphosphate; Aging; Alzheimer Disease; Animals; Brain; Cell Line; Cognition Disorders; Fe | 2016 |
Sociodemographic and lifestyle risk factors for incident dementia and cognitive decline in the HYVET.
Topics: Aged, 80 and over; Aging; Alcohol Drinking; Antihypertensive Agents; Cognition Disorders; Dementia; | 2009 |
Treatment strategies targeting excess hippocampal activity benefit aged rats with cognitive impairment.
Topics: Age Factors; Aging; Animals; Anticonvulsants; CA3 Region, Hippocampal; Cognition Disorders; Disease | 2010 |
Treatment strategies targeting excess hippocampal activity benefit aged rats with cognitive impairment.
Topics: Age Factors; Aging; Animals; Anticonvulsants; CA3 Region, Hippocampal; Cognition Disorders; Disease | 2010 |
Treatment strategies targeting excess hippocampal activity benefit aged rats with cognitive impairment.
Topics: Age Factors; Aging; Animals; Anticonvulsants; CA3 Region, Hippocampal; Cognition Disorders; Disease | 2010 |
Treatment strategies targeting excess hippocampal activity benefit aged rats with cognitive impairment.
Topics: Age Factors; Aging; Animals; Anticonvulsants; CA3 Region, Hippocampal; Cognition Disorders; Disease | 2010 |
Effect of Convolvulus pluricaulis Choisy and Asparagus racemosus Willd on learning and memory in young and old mice: a comparative evaluation.
Topics: Acetylcholine; Aging; Animals; Antioxidants; Cholinergic Agents; Convolvulus; Dose-Response Relation | 2010 |
Cortico-hippocampal hyperexcitability in synapsin I/II/III knockout mice: age-dependency and response to the antiepileptic drug levetiracetam.
Topics: 4-Aminopyridine; Aging; Analysis of Variance; Animals; Anticonvulsants; Cerebral Cortex; Disease Mod | 2010 |
Ascorbic Acid: a promising memory-enhancer in mice.
Topics: Aging; Amnesia; Animals; Antioxidants; Anxiety; Ascorbic Acid; Avoidance Learning; Behavior, Animal; | 2003 |
Tolerability of levetiracetam in elderly patients with CNS disorders.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aging; Anticonvulsants; Anxiety Disorders; Central Nervo | 2003 |
Chronic levetiracetam treatment early in life decreases epileptiform events in young GAERS, but does not prevent the expression of spike and wave discharges during adulthood.
Topics: Aging; Animals; Anticonvulsants; Brain; Electrodes, Implanted; Electroencephalography; Epilepsy; Lev | 2005 |
Piracetam improves mitochondrial dysfunction following oxidative stress.
Topics: Adenosine Triphosphate; Aging; Animals; Antioxidants; Brain; Caspase 9; Culture Media, Serum-Free; F | 2006 |
Hyponatremia from oxcarbazepine and carbamazepine.
Topics: Adult; Age Factors; Aging; Anticonvulsants; Carbamazepine; Databases, Factual; Dose-Response Relatio | 2005 |
Changes in motor activity with age and the effects of pharmacologic treatment.
Topics: Aging; Animals; Body Weight; Dextroamphetamine; Dihydroergotoxine; Female; Meclofenoxate; Motor Acti | 1984 |
Effects of centrophenoxine, piracetam and hydergine on rat brain lipid peroxidation.
Topics: Aging; Animals; Brain; Dihydroergotoxine; Glycolates; In Vitro Techniques; Lipid Peroxides; Male; Me | 1981 |
[Age dependent changes in organs and the significance for drug therapy].
Topics: Aged; Aging; Drug Therapy; Erythrocyte Count; Erythrocytes; Female; Humans; Kidney; Male; Middle Age | 1983 |
Profound effects of combining choline and piracetam on memory enhancement and cholinergic function in aged rats.
Topics: Acetylcholine; Aging; Animals; Brain Chemistry; Choline; Male; Memory; Parasympathetic Nervous Syste | 1981 |
Effects of piracetam on indices of cognitive function in a delayed alternation task in young and aged rats.
Topics: Aging; Animals; Cognition; Conditioning, Operant; Dose-Response Relationship, Drug; Male; Memory, Sh | 1994 |
Effects of cytidine diphosphate choline on rats with memory deficits.
Topics: Aging; Animals; Avoidance Learning; Clonidine; Cytidine Diphosphate Choline; Electroshock; Fetal Alc | 1993 |
Effects of piracetam on N-methyl-D-aspartate receptor properties in the aged mouse brain.
Topics: Administration, Oral; Aging; Animals; Binding Sites; Brain; Dizocilpine Maleate; Female; Mice; Pirac | 1993 |
Effect of chronic piracetam on age-related changes of cross-maze exploration in mice.
Topics: Aging; Animals; Exploratory Behavior; Male; Memory; Mice; Mice, Inbred C57BL; Mice, Inbred CBA; Noot | 1995 |
Effects of piracetam on membrane fluidity in the aged mouse, rat, and human brain.
Topics: Aged; Aging; Animals; Brain; Female; Humans; Male; Membrane Fluidity; Mice; Neuroprotective Agents; | 1997 |
[Effect of piracetam administration during lactation on morphometric parameters of neocortex and hippocampus of one month old rats].
Topics: Aging; Animals; Animals, Suckling; Cerebral Cortex; Female; Hippocampus; Male; Neurons; Nootropic Ag | 1997 |
Piracetam improves cognitive performance by restoring neurochemical deficits of the aged rat brain.
Topics: Age Factors; Aging; Analysis of Variance; Animals; Anisotropy; Avoidance Learning; Brain Chemistry; | 1999 |
Renal handling of drugs in the healthy elderly. Creatinine clearance underestimates renal function and pharmacokinetics remain virtually unchanged.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aging; Atenolol; Creatinine; Diuretics; Female; Glomerular | 1999 |
Effect of piracetam administration on 3H-N-methylscopolamine binding in cerebral cortex of young and old rats.
Topics: Aging; Animals; Binding, Competitive; Female; Kinetics; Male; Motor Cortex; N-Methylscopolamine; Par | 1992 |
CGS 5649 B, a new compound, reverses age-related cognitive dysfunctions in rats.
Topics: Aging; Animals; Avoidance Learning; Dose-Response Relationship, Drug; Ergoloid Mesylates; Fumarates; | 1992 |
Age-related changes of the effects of a group of nootropic drugs on the content of rat brain biogenic monoamines.
Topics: Aging; Animals; Biogenic Monoamines; Brain Chemistry; Male; Piracetam; Psychotropic Drugs; Pyrrolidi | 1991 |
Effects of age and drugs on food and fluid intake.
Topics: Aging; Amphetamines; Animals; Behavior, Animal; Benzodiazepines; Body Weight; Diazepam; Drinking; Dr | 1991 |
Abnormalities of energy metabolism in Alzheimer's disease studied with PET.
Topics: Adult; Aged; Aging; Alzheimer Disease; Brain; Deoxyglucose; Energy Metabolism; Fluorodeoxyglucose F1 | 1991 |
Effects of nootropic agents on the performing of active two-way avoidance tasks in young and old rats.
Topics: Aging; Animals; Avoidance Learning; Male; Meclofenoxate; Memory; Piracetam; Psychotropic Drugs; Rats | 1990 |
Influence of nootropic drugs on the age-dependent potassium-coupling of transmitter release.
Topics: Aging; Animals; Calcium-Transporting ATPases; Dopamine; Dose-Response Relationship, Drug; Meclofenox | 1990 |
Effects of indeloxazine hydrochloride on passive avoidance behavior of senescence-accelerated mice.
Topics: Aging; Animals; Antidepressive Agents; Avoidance Learning; Cognition; Cycloheximide; Dihydroergotoxi | 1989 |
Piracetam elevates muscarinic cholinergic receptor density in the frontal cortex of aged but not of young mice.
Topics: Aging; Animals; Atropine; Cerebral Cortex; Female; Male; Mice; Oxotremorine; Piracetam; Pyrrolidinon | 1988 |
Chronic treatment with piracetam elevates muscarinic cholinergic receptor density in the frontal cortex of aged mice.
Topics: Aging; Animals; Brain Chemistry; Cerebral Cortex; Female; In Vitro Techniques; Mice; Piracetam; Pyrr | 1988 |
Effects of oxiracetam on learning and memory in animals: comparison with piracetam.
Topics: Aging; Animals; Avoidance Learning; Drug Administration Schedule; Electroshock; Memory; Mice; Pirace | 1986 |
The predictive value of animal experimentation for clinical geropsychopharmacology.
Topics: Aging; Animals; Brain; Cats; Corpus Callosum; Evoked Potentials; Humans; Learning; Piracetam; Pyrrol | 1986 |
[Effect of nootropil on the ultrastructure of the cerebral cortex of the aged rat].
Topics: Aging; Animals; Capillaries; Cerebral Cortex; Microscopy, Electron; Neuroglia; Phagocytosis; Piracet | 1986 |
The effect of age on clinical pharmacokinetics of piracetam.
Topics: Adult; Aged; Aging; Blood Proteins; Body Weight; Erythrocytes; Female; Half-Life; Humans; Kinetics; | 1985 |
Arousal deficit shown in aged rat's quantitative EEG and ameliorative action of pramiracetam compared to piracetam.
Topics: Aging; Animals; Cerebral Cortex; Electroencephalography; Hippocampus; Male; Piracetam; Pyrrolidines; | 1985 |
Basic mechanisms of aging.
Topics: Acetylglucosaminidase; Aging; Animals; Brain; Cathepsins; Cytoplasm; Diaphragm; DNA; Glucuronidase; | 1974 |